[131]I-hypericin | 1159569-82-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 芘
• 英文名称: [131]I-hypericin
• 英文别名: [131]I-Hyp
• CAS: 1159569-82-0
• 化学式: C₃₀H₁₅IO₈
• 分子量: 634.444
• InChiKey: QCZMLQMQBDQJPV-ACYMOGTASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.69
• 重原子数：
  39.0
• 可旋转键数：
  0.0
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  155.52
• 氢给体数：
  6.0
• 氢受体数：
  8.0

反应信息

• 作为产物：
  描述：

  hypericin 在 sodium iodide 、 1,3,4,6-四氯-3α,6α-二苯基甘脲 作用下， 生成 [131]I-hypericin
  参考文献：
  名称：

  用于肝细胞癌消融后残留肿瘤的坏死靶向、荧光/SPECT 成像和放射治疗的多模式治疗诊断纳米颗粒

  摘要：

  热消融已被普遍用作肝细胞癌的有效治疗方法。然而，消融后坏死周围肿瘤残留在肿瘤复发和不良预后中起着重要作用。因此，迫切需要开发能够有效靶向并消除残留肿瘤的药物。坏死靶向策略对于评估肿瘤坏死区域和治疗周围残留肿瘤具有潜在意义。为了解决这个问题，我们开发了一种具有坏死亲合力的可生物降解纳米颗粒，它与荧光成像、单光子发射计算机断层扫描 (SPECT) 成像和坏死靶向放射治疗兼容。以碘131标记的金丝桃素（ 131 I-Hyp）为核心，两亲性共聚物聚（乙二醇）-嵌段-聚（ε-己内酯）（PEG-PCL）为壳合成纳米颗粒。通过低温透射电子显微镜（cryo-TEM）和动态光散射分析（多分散指数）测定，所开发的纳米颗粒 PNP@（ 131 I-Hyp）具有均匀的球形形态，尺寸为 33.07 ± 3.94 和 45.93 ± 0.58 nm =0.19±0.01)，并在体外具有良好的稳定性和血液相容性。在小鼠皮下消融残留肿瘤模型中，荧光和

  DOI：

  10.1021/acs.molpharmaceut.3c01081

文献信息

• Synthesis and Evaluation of ¹³¹I-Skyrin as a Necrosis Avid Agent for Potential Targeted Radionuclide Therapy of Solid Tumors
  作者：Cong Wang、Qiaomei Jin、Shengwei Yang、Dongjian Zhang、Qin Wang、Jindian Li、Shaoli Song、Ziping Sun、Yicheng Ni、Jian Zhang、Zhiqi Yin

  DOI：10.1021/acs.molpharmaceut.5b00630

  日期：2016.1.4

  An innovative anticancer approach targeted to necrotic tissues, which serves as a noncancerous and generic anchor, may present a breakthrough. Necrosis avid agents with a flat conjugate aromatic structure selectively accumulate in necrotic tissues, but they easily form aggregates that undesirably distribute to normal tissues. In this study, skyrin, a dianthraquinone compound with smaller and distorted pi-cores and thus decreased aggregates as compared with hypericin (Hyp), was designed to target necrosis for tumor therapy. Aggregation studies of skyrin by UV/vis spectroscopy showed a smaller selfassociation constant with skyrin than with Hyp. Skyrin was labeled by iodine-131 with a radiochemical purity of 98% and exhibited good stability in rat serum for 72 h. In vitro cell uptake studies showed significant difference in the uptake of I-131-skyrin by necrotic cells compared to normal cells (P < 0.05). Compared in rats with liver and muscle necrosis, radiobiodistribution, whole-body autoradiography, and SPECT/CT studies revealed higher accumulation of I-131-skyrin in necrotic liver and muscle (p < 0.05), but lower uptake in normal organs, relative to that of I-131-Hyp. In mice bearing H22 tumor xenografts treated with combretastatin A4 disodium phosphate, the highest uptake of I-131-skyrin was found in necrotic tumor. In conclusion, I-131-skyrin appears a promising agent with reduced accumulation in nontarget organs for targeted radionuclide therapy of solid tumors.
• A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [iodogen] dissolved in dimethyl sulphoxide (DMSO)
  作者：Marlein Miranda Cona、Junjie Li、Feng Chen、Yuanbo Feng、Yeranddy Aguiar Alpizar、Florent Vanstapel、Karel Talavera、Peter de Witte、Alfons Verbruggen、Ziping Sun、Raymond Oyen、Yicheng Ni

  DOI：10.3109/00498254.2012.756559

  日期：2013.8

  1. Iodogen (tetrachloro-diphenyl glycoluril) dissolved in DMSO (dimethyl sulphoxide) appears indispensable in radioiodination of hypericin for a new anticancer strategy. We studied the safety of intravenously administered iodogen/DMSO in mice (n = 132).2. Median lethal dose (LD50) of iodogen/DMSO was determined with doses of 40.0, 50.0, 55.0, 60.0, 65.0 and 70.0 mg/kg. Next, toxicity of iodogen/DMSO at 30.0 mg/kg was evaluated using saline and DMSO as controls. Changes in behaviour, body weight and serum biochemistry were evaluated. Histopathology of lungs, heart, liver and kidney was performed.3. LD50 values of iodogen/DMSO were 59.5 mg/kg (95% confidence limits (CI): 54.1-65.4 mg/kg) and 61.0 mg/kg (95% CI: 56.2-66.2 mg/kg) for female and male mice, respectively. Similar to that of control groups, no animal deaths were encountered after iodogen/DMSO administration at 30.0 mg/kg. Body weights over 24 h were not altered in all groups, but significantly higher in iodogen/DMSO and DMSO groups (p<0.05) 14 d post-injection. Blood urea nitrogen and alkaline phosphatase increased (p<0.05) in iodogen/DMSO group without clinical symptoms. No pathologies were found by gross and microscopic inspection.4. A single dose of iodogen/DMSO up to 30.0 mg/kg, over 3000 times the dose in potential human applications, appears safe, with an LD50 doubling that dose in mice.